BETAPAR
Clinical safety rating: caution
Comprehensive clinical and safety monograph for BETAPAR (BETAPAR).
Beta-2 adrenergic receptor agonist that stimulates adenylyl cyclase, increasing cAMP levels, leading to bronchodilation.
| Metabolism | Metabolized primarily by CYP3A4, with minor contributions from CYP2D6 and CYP2C19. |
| Excretion | Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%; the remainder undergoes hepatic metabolism. |
| Half-life | Terminal elimination half-life is 3-5 hours in patients with normal renal function; prolonged to 10-20 hours in severe renal impairment (CrCl <30 mL/min). |
| Protein binding | 85-90% bound to albumin. |
| Volume of Distribution | Vd approximately 0.8-1.2 L/kg, indicating distribution into total body water and some tissue binding. |
| Bioavailability | Oral bioavailability is 70-80% due to first-pass metabolism; intravenous bioavailability is 100%. |
| Onset of Action | Oral: 30-60 minutes; intravenous: 2-5 minutes. |
| Duration of Action | Oral: 6-8 hours; intravenous: 4-6 hours. Duration may be extended in renal impairment or with sustained-release formulations. |
| Action Class | Glucocorticoids |
| Brand Substitutes | Betanat 4mg Injection, Betamax 4mg Injection, Nbet 4mg Injection, Betjec 4mg Injection, Betavol 4mg Injection |
Initial: 25 mg orally twice daily; may increase gradually to 100 mg twice daily based on tolerance and response.
| Dosage form | TABLET |
| Renal impairment | No dosage adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment (CrCl <30 mL/min); use with caution. |
| Liver impairment | Contraindicated in patients with severe hepatic impairment (Child-Pugh class C). For moderate impairment (Child-Pugh class B), use with caution and consider starting at 25 mg once daily. |
| Pediatric use | Safety and efficacy not established in pediatric patients; use not recommended. |
| Geriatric use | Start at 25 mg once daily; increase slowly based on tolerability. Monitor renal function and vital signs closely. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for BETAPAR (BETAPAR).
| Breastfeeding | Betamethasone enters breast milk in low concentrations (M/P ratio approximately 0.3-0.5). At maternal doses <80 mg/day, infant exposure is minimal and unlikely to cause adverse effects. Monitor infant for adrenal suppression if prolonged high-dose maternal therapy. |
| Teratogenic Risk | Betapar (betamethasone) is a corticosteroid. In first trimester: association with oral clefts (odds ratio ~1.3-3.3) based on observational studies. Second/third trimester: risk of fetal growth restriction, adrenal suppression, and potential long-term neurodevelopmental effects. Use only if maternal benefit outweighs risks. |
■ FDA Black Box Warning
Long-acting beta-2 agonists (LABA) increase the risk of asthma-related death. Therefore, LABA should only be used as add-on therapy for patients not adequately controlled on inhaled corticosteroids.
| Serious Effects |
Hypersensitivity to any component of the product.
| Precautions | Asthma-related death; paradoxical bronchospasm; cardiovascular effects (increased heart rate, hypertension); hypokalemia; hyperglycemia; immediate hypersensitivity reactions. |
| Food/Dietary | No significant food interactions; however, avoid excessive alcohol intake as it may enhance hypotensive effects. |
| Clinical Pearls |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, and signs of infection. Fetal monitoring includes ultrasound for growth restriction, amniotic fluid assessment, and nonstress test/biophysical profile if prolonged therapy. Neonatal monitoring for adrenal insufficiency after delivery. |
| Fertility Effects | Betamethasone may suppress hypothalamic-pituitary-adrenal axis and gonadotropin secretion, potentially causing menstrual irregularities and temporary fertility impairment. No evidence of permanent infertility. |
| BETAPAR (betaxolol) is a cardioselective beta-1 blocker used for hypertension and glaucoma. Due to beta-1 selectivity, it may be safer in patients with asthma or COPD compared to non-selective beta-blockers, but caution is still advised. Intraocular formulation reduces systemic absorption; however, monitor for bradycardia and heart block in susceptible patients. Abrupt withdrawal may exacerbate angina or hypertension. |
| Patient Advice | Do not stop taking this medication suddenly; talk to your doctor before discontinuing. · Take as prescribed, usually once daily, with or without food. · Monitor for signs of slow heart rate (dizziness, fainting) or breathing difficulty. · If using eye drops, apply pressure to the tear duct for 1 minute after instillation to minimize systemic absorption. · Inform all healthcare providers you are taking betaxolol. |